Parameter Identifiability of Fundamental Pharmacodynamic Models
暂无分享,去创建一个
Neil D. Evans | Mats Jirstrand | Michael J. Chappell | David L. I. Janzén | Linnéa Bergenholm | Joanna Parkinson | James Yates | M. Jirstrand | M. Chappell | N. Evans | J. Yates | L. Bergenholm | David Janzén | J. Parkinson | Linnéa Bergenholm
[1] R. Bellman,et al. On structural identifiability , 1970 .
[2] Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations , 2016, The AAPS Journal.
[3] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[4] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.
[5] M. J. Chapman,et al. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. , 2004, Mathematical biosciences.
[6] The Input-Output Relationship Approach to Structural Identifiability Analysis , 2010 .
[7] M J Chappell,et al. Structural identifiability of models characterizing saturable binding: comparison of pseudo-steady-state and non-pseudo-steady-state model formulations. , 1996, Mathematical biosciences.
[8] Meindert Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.
[9] Johan Gabrielsson,et al. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[10] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[11] M. Chappell,et al. PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. , 2016, Journal of pharmacological and toxicological methods.
[12] S. Visser,et al. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. , 2013, Journal of pharmacological and toxicological methods.
[13] Michael Rowley,et al. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.
[14] Johan Karlsson,et al. An Efficient Method for Structural Identifiability Analysis of Large Dynamic Systems , 2012 .
[15] Neil D. Evans,et al. Structural identifiability of surface binding reactions involving heterogeneous analyte: Application to surface plasmon resonance experiments , 2013, Autom..
[16] Keith R. Godfrey,et al. An Identifiability Analysis of a Parent–Metabolite Pharmacokinetic Model for Ivabradine , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[17] Meindert Danhof,et al. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. , 2009, Drug metabolism and pharmacokinetics.
[18] M. Gastonguay,et al. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations , 2015, The AAPS Journal.
[19] Ursula Klingmüller,et al. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood , 2009, Bioinform..
[20] Arthur A M Wilde,et al. Cardiac ion channels in health and disease. , 2010, Heart rhythm.
[21] James W. T. Yates,et al. The design and analysis of parallel experiments to produce structurally identifiable models , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Leif Carlsson,et al. Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In Vivo , 2009, Journal of cardiovascular pharmacology.
[23] D. Jonker,et al. A Pharmacokinetic‐pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical QT Prolongation from Human Ether‐a‐go‐go‐related Gene Current Inhibition Data , 2005, Clinical pharmacology and therapeutics.
[24] J. Valentin,et al. An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.
[25] O Della Pasqua,et al. Assessing the Probability of Drug‐Induced QTc‐Interval Prolongation During Clinical Drug Development , 2011, Clinical pharmacology and therapeutics.
[26] Johan Karlsson,et al. Comparison of approaches for parameter identifiability analysis of biological systems , 2014, Bioinform..